%0 Generic %A L., Zhao %A F., Ma %A Y., Yu %A Y., Li %A Y., Wang %A L., He %A M., Zhou %A X., Tian %A R., Jing %A L., Li %A C., Huang %A M., Bai %A S., Sun %D 2019 %T Supplementary Material for: Regional Citrate Anticoagulation versus No-Anticoagulation for Continuous Venovenous Hemofiltration in Acute Severe Hypernatremia Patients with Increased Bleeding Risk: A Retrospective Cohort Study %U https://karger.figshare.com/articles/dataset/Supplementary_Material_for_Regional_Citrate_Anticoagulation_versus_No-Anticoagulation_for_Continuous_Venovenous_Hemofiltration_in_Acute_Severe_Hypernatremia_Patients_with_Increased_Bleeding_Risk_A_Retrospective_Cohort_Study/9821213 %R 10.6084/m9.figshare.9821213.v1 %2 https://karger.figshare.com/ndownloader/files/17616740 %2 https://karger.figshare.com/ndownloader/files/17616743 %2 https://karger.figshare.com/ndownloader/files/17616746 %2 https://karger.figshare.com/ndownloader/files/17616749 %K Acute severe hypernatremia %K Continuous venovenous hemofiltration %K Regional citrate anticoagulation %K No-anticoagulation %K Increased bleeding risk %K Serum sodium reduction rate %X Purpose: This study was aimed at evaluating the efficacy and safety of regional citrate anticoagulation (RCA) versus no-anticoagulation continuous venovenous hemofiltration (CVVH) in acute severe hypernatremia patients with increased bleeding risk. Materials and Methods: Acute severe hypernatremia patients with high bleeding risk who underwent CVVH in our center between January 2011 and October 2017 were considered as candidates. Patients who were <18 years old, with hypovolemic hypernatremia, and had systemic anticoagulation were excluded. The included patients were divided into RCA and no-anticoagulation groups according to their anticoagulation strategy during CVVH and matched by age, sequential organ failure assessment scores, and vasopressor dependency. Results: Of the 64 included patients, no-anticoagulation and RCA were employed for CVVH in 23 and 41 patients, respectively. The serum sodium reduction rate (RRSeNa) was not significantly different between the no-anticoagulation and RCA groups (p = 0.729). Compared to no-anticoagulation, RCA significantly prolonged the circuit survival time (15 h [4.1–23.9] vs. 51 h [21.3–80.7], p = 0.001). The incidence of filter failure was 65.2% (15/23) in the no-anticoagulation group and 2.4% (1/41) in the RCA group (p < 0.001), respectively. In the matched cohort, the RRSeNas were not different between the 2 groups (p = 0.569), and the filter lifespan was significantly longer in the RCA group as well (p < 0.001). Conclusion: RCA might be safe and effective for acute severe hypernatremia patients who underwent CVVH treatment. Further prospective, randomized, control trials are warranted to obtain robust evidences. %I Karger Publishers